Previous 10 | Next 10 |
The following slide deck was published by Assembly Biosciences, Inc. in conjunction with this Read more ...
Assembly Biosciences (NASDAQ: ASMB ): Q1 GAAP EPS of -$1.05 beats by $0.01 . More news on: Assembly Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN FRANCISCO, May 09, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today reported financial results for the first ...
Assembly Biosciences (NASDAQ: ASMB ) COO and CFO Graham Cooper has resigned to pursue other interests. A search has been initiated for a successor. More news on: Assembly Biosciences, Inc., Healthcare stocks news, Read more ...
SAN FRANCISCO, May 02, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of David R. Hou...
SAN FRANCISCO, April 22, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Steven J. Knox has joine...
On April 12th, Altimmune ( ALT ) presented Phase I HepTcell data at the International Liver Congress in Vienna, Austria. Altimmune's immunotherapeutic synthetic peptide vaccine candidate demonstrated admirable safety and justified the company's plan to move into a Phase II study. Admittedly,...
Gainers : Fibrocell Science (NASDAQ: FCSC ) +52% . Bio-Path Holdings (NASDAQ: BPTH ) +40% . Vectrus (NYSE: VEC ) +27% . Electronics for Imaging (NASDAQ: EFII ) +27% . SSLJ.com (NASDAQ: SSLJ ) +22% . ATA (NASDAQ: ATAI ) +21% . Advanced Disposal Services (NYSE: ADSW ) +19% . Amy...
Thinly traded micro cap Assembly Biosciences ( ASMB -25.3% ) is down out the gate this morning on the heels of interim data from two Phase 2a clinical trials evaluating antiviral candidate ABI-H0731 (731) in patients with hepatitis B virus (HBV) infection. The results were presented at T...
- Favorable safety and tolerability profile - Superior antiviral activity with ABI-H0731 in combination with nucleos(t)ide therapies - Selected for inclusion in “Best of ILC” presentation - Company to host conference call Monday, April 15, 2019 at 8am EDT SAN FRANC...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...